Correlation Engine 2.0
Clear Search sequence regions

  • blood (1)
  • hiv 1 (7)
  • patients (8)
  • plasma (5)
  • rna (1)
  • Sizes of these terms reflect their relevance to your search.

    Little is known about HIV-1 integrase inhibitor resistance in the CNS. This study aimed to evaluate integrase inhibitor resistance in CSF, as a marker of the CNS, and compare it with the resistance in plasma. HIV integrase was sequenced both in plasma and CSF for 59 HIV-1 patients. The clinical and biological data were collected from clinical routine care. Among the 59 HIV-1 patients, 32 (54.2%) were under antiretroviral (ARV) treatment. The median (IQR) HIV-1 RNA in the plasma of viraemic patients was 5.32 (3.85-5.80) and 3.59 (2.16-4.50) log10 copies/mL versus 4.79 (3.56-5.25) and 3.80 (2.68-4.33) log10 copies/mL in the CSF of ARV-naive and ARV-treated patients, respectively. The patients were mainly infected with non-B subtypes (72.2%) with the most prevalent recombinant form being CRF02_AG (42.4%). The HIV-1 integrase sequences from CSF presented resistance mutations for 9/27 (33.3%) and 8/32 (25.0%) for ARV-naive (L74I, n = 3; L74I/M, n = 1; T97A, n = 1; E157Q, n = 4) and ARV-treated (L74I, n = 6; L74M, n = 1; T97A, n = 1; N155H, n = 1) patients, respectively. Integrase inhibitor resistance mutations in CSF were similar to those in plasma, except for 1/59 patients. This work shows similar integrase inhibitor resistance profiles in the CNS and plasma in a population of HIV-1 viraemic patients. © The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For permissions, please email:


    Basma Abdi, Mouna Chebbi, Marc Wirden, Elisa Teyssou, Sophie Sayon, Romain Palich, Sophie Seang, Marc-Antoine Valantin, Anne Simon, Roland Tubiana, Christine Katlama, Vincent Calvez, Anne-Geneviève Marcelin, Cathia Soulie. No difference in HIV-1 integrase inhibitor resistance between CSF and blood compartments. The Journal of antimicrobial chemotherapy. 2021 May 12;76(6):1553-1557

    PMID: 33693680

    View Full Text